Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03996031 · ClinicalTrials.gov registry record
Plan to Thrive: Extending Cancer Survivorship Care Beyond the Clinic
A clinical trial, sponsored by Northwestern University.
- Completed
- Registry status
- 33
- Enrollment target
NCT03996031: Completed study, sponsored by Northwestern University.
NCT03996031 is a clinical trial that has completed, run by Northwestern University. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03996031 has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to test the usability of the Plan To Thrive smartphone application with cancer survivors. This study will involve three visits (baseline, follow-up, and feedback assessments). Between the baseline and follow-up time points, patients will undergo a 90-day period in which they will engage with app content. It is hypothesized that cancer survivors in this study will find the smartphone application, Plan to Thrive, an acceptable and feasible way to access post-treatment information. In addition, the investigators will explore preliminary efficacy by examining changes over time in primary (patient activation, patient knowledge and adherence to follow-up care recommendations and health behaviors) and secondary outcomes \[symptom burden, health-related quality of life and patient satisfaction\].
Primary Outcome
The investigators will explore the feasibility of the study procedures by examining rates of enrollment (defined as the percent of eligible individuals who consent to participate).
Interventions
- DEVICE Plan to Thrive smartphone application
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2019-08-19 |
| Est. Completion | 2019-12-31 |
What the finished NCT03996031 record still lists
NCT03996031 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 33 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Plan to Thrive smartphone application is the first listed.
NCT03996031 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03996031 about?
NCT03996031 is a clinical study titled "Plan to Thrive: Extending Cancer Survivorship Care Beyond the Clinic". The purpose of this study is to test the usability of the Plan To Thrive smartphone application with cancer survivors. This study will involve three visits (baseline, follow-up, and feedback assessments). Between the baseline and follow-up time points, patients will undergo a 90-day period in which ...
What is the current status of trial NCT03996031?
This trial is currently completed. The enrollment target is 33 participants. The study started on 2019-08-19. Estimated completion is 2019-12-31.
What interventions are being tested in trial NCT03996031?
The interventions under investigation include: Plan to Thrive smartphone application (DEVICE).
Who is sponsoring clinical trial NCT03996031?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI